title: Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says
source: Yahoo
date: 2025-10-08
url: https://finnhub.io/api/news?id=c302e5b61bd685ba464983de1216de8b164e4229bb67f1b2ccabe44038474cd8
Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics (
